Several neuroendocrine responses occur in heart failure. The vasoconstrictor and sodium retentive forces seem to overrule the counterbalancing vasodilative systems.12 The use of angiotensin converting enzyme inhibitors in treating congestive heart failure is one neuroendocrinological approach to correct this imbalance.3 Atrial natriuretic peptide is a hormone with vasodilating and natriuretic properties.45 Its secretion from the myocytes is probably modulated by stretch receptors.6-8 In most circumstances this peptide seems to suppress the renin-angiotensin-aldosterone system.9-"1 Thus, it may be regarded as a hormone counteracting excessive vasoconstrictive and sodium retentive forces, including activation of the renin-angiotensin-aldosterone system, as are found in patients with congestive heart failure.
Subjects-38 Patients with stable congestive heart failure caused by ischaemic heart disease. Methods-Data were collected over a 24 hour period and assessed with the aim of distinguishing between the' haemodynamic effects on plasma concentrations of atrial natriuretic peptide and the direct effects of the study drug, vasopressin concentrations, and angiotensin converting enzyme activity. Results-Pulmonary capillary wedge pressure was the main predictor of the plasma concentration of atrial natriuretic peptide. A higher plasma concentration of this peptide with a given pulmonary capillary wedge pressure was found after 24 hours of treatment with 2'5 mg and 5 mg of ramipril. Plasma concentration of the active metabolite, change in arginine vasopressin concentration or degree of angiotensin converting enzyme inhibition did not significantly predict change in plasma concentration of atrial natriuretic peptide or in the ratio of atrial natriuretic peptide concentration to pulmonary capillary wedge pressure. Conclusions-A gradual increase in plasma concentration of atrial natriuretic peptide with a given pulmonary capillary wedge pressure, occurs during short term high degree inhibition of angiotensin converting enzyme. The causative mechanisms are yet to be identified. Such a change in the relation between central haemodynamics and atrial natriuretic peptide concentration may contribute to the beneficial effects of angiotensin converting enzyme inhibition in patients with congestive heart failure due to ischaemic heart disease.
(Br Heart _T 1994;72:521-527) Several neuroendocrine responses occur in heart failure. The vasoconstrictor and sodium retentive forces seem to overrule the counterbalancing vasodilative systems. 12 The use of angiotensin converting enzyme inhibitors in treating congestive heart failure is one neuroendocrinological approach to correct this imbalance.3 Atrial natriuretic peptide is a hormone with vasodilating and natriuretic properties. 45 Its secretion from the myocytes is probably modulated by stretch receptors. [6] [7] [8] In most circumstances this peptide seems to suppress the renin-angiotensin-aldosterone system.9-"1 Thus, it may be regarded as a hormone counteracting excessive vasoconstrictive and sodium retentive forces, including activation of the renin-angiotensin-aldosterone system, as are found in patients with congestive heart failure.
In vivo intravenous administration of vasopressin, angiotensin II, noradrenaline, and endothelin increases the plasma concentration of atrial natriuretic peptide."2-14 All these substances are potent vasoconstrictors with systemic and central pressure effects, which could explain the increase in the plasma concentration of this peptide. Whether this is the sole cause of the atrial natriuretic peptide release produced by these substances in vivo remains to be determined. In a rat heart-lung preparation, the addition of angiotensin II or vasopressin to the perfusate did not significantly affect the basal secretion of atrial natriuretic peptide, or response of this secretion to increasing venous return, indicating that the ability of these hormones to facilitate atrial natriuretic peptide secretion in vivo may be secondary to their effects on atrial pressures. '5 In a study in which atrial pressures were kept constant by simultaneous nitroprusside infusion, the effect of phenylephrine on the plasma concentration of atrial natriuretic peptide was abolished, while the effect of angiotensin II was maintained. '6 Atrial 
Patients and methods
The study comprised 38 patients with heart failure (functional class III of the New York Heart Association classification) due to ischaemic heart disease. There were nine women and 29 men, with a mean age of 67 (SD 7) years (range 51-77).
The patients were randomly allocated to one of four treatment groups and received either placebo or one of three doses of oral ramipril. All patients had been clinically stable for a minimum of four weeks before entering the study, and treatment was restricted to diuretics, digoxin, and fi blockers which were unchanged in dosage during this stabilisation period. The 
Differences in responses between the groups
Influence of angiotensin converting enzyme inhibition on the relaion ofatrial natriueretic peptide concentration to atrial pressure in heartfailure (27) 41 (19) 43 (19) 44 (18) line and 24 hours in the groups that were given 2-5 mg and 5 mg of ramipril (both P values = 003) (table 3) . The change in the ratio of atrial natriuretic peptide concentration to pulmonary capillary wedge pressure from baseline to 24 hours was not related to the baseline pulmonary capillary wedge pressure (simple regression). A multiple regression analysis was performed to test for possible influence of the previously tested haemodynamic parameters on this ratio. There were no significant interactions between the ratio and these parameters, apart from pulmonary capillary wedge pressure and atrial natriuretic peptide concentration, as was to be expected. The calculated change in the ratio of atrial natriuretic peptide concentration to pulmonary capillary wedge pressure was not influenced by any of the above differences but was exclusively dependent on the change in atrial natriuretic peptide concentration and change in pulmonary capillary wedge pressure.
In the placebo group there was a significant relation between change in pulmonary capillary wedge pressure and plasma concentration of atrial natriuretic peptide at 3, 6, and 24 hours (rvalues 0 77, 0 70, and 0-78 and P values 0-01, 0'03, and 0'008, respectively). The treatment group receiving 1X25 mg of ramipril had a similar relation between change in these variables at 6 and 24 hours (r > 070 and P < 0'03), but not at 3 hours. There were no significant relations between change in pulmonary capillary wedge pressure and change in plasma concentration of atrial natriuretic peptide in the groups receiving the two higher doses of ramipril.
RAMIPRILAT AND ARGININE VASOPRESSIN CONCENTRATIONS, ENZYME ACTIVITIES, AND HAEMODYNAMIC DATA Table 4 shows the relations between plasma concentrations of ramiprilat and haemodynamic alterations. No significant correlations with right atrial mean pressure, cardiac index, or plasma renin activity were found.
The change in pulmonary capillary wedge pressure was also proportional to the degree of angiotensin converting enzyme inhibition (r values 0-43-048; P values 001-0'03).
The degree of inhibition of angiotensin converting enzyme was proportional to the ramiprilat concentration, with a 50% inhibition around 1 ng/ml and total inhibition around 7 ng/ml. The inhibition was long standing, amounting to 87%, 24 pressin concentration, ramiprilat concentration, and atrial natriuretic peptide concentration, or with changes in these parameters (multiple regression).
Discussion
Atrial natriuretic peptide may be an important modulator of the complex neuroendocrinological adaptations in heart failure. '29 Endogenous atrial natriuretic peptide has a significant vasodilator role in heart failure in studies using antibodies against this peptide in rats with chronic congestive heart failure.30 Lee et Pulmonary capillary wedge pressure, the main predictor of plasma concentrations of atrial natriuretic peptide in our study, was significantly reduced when compared with the placebo group during the first 24 hours in the groups that were given 2-5 mg and 5 mg of oral ramipril. In contrast, the change in plasma concentration of atrial natriuretic peptide did not differ significantly between the groups. The plasma concentration of atrial natriuretic peptide was, however, lowest at three hours after baseline in all groups, with a tendency to return towards baseline values at 24 hours. This increase between three and 24 hours may be explained by a proportional increase in pulmonary capillary wedge pressure in the placebo group and the group given 1 25 mg ramipril. Further support for this view is provided by the significant relation between change in pulmonary capillary wedge pressure and change in plasma concentrations of atrial natriuretic peptide in these groups. In the patients who received 2-5 mg and 5 mg ramipril the persistence of a significant reduction of this pressure at 24 hours makes another explanation necessary. In these patients the relation between change in pulmonary capillary wedge pressure and change in peptide concentration was lost. One possibility is that this observation reflects a fairly slow adaptive mechanism, in contrast to the rapid responsiveness to haemodynamic interventions previously reported.7 Alternatively, the cause may be a direct effect of the metabolite itself or alterations in the reninangiotensin-aldosterone system caused by changes in the angiotensin converting enzyme activity. These putative explanations were further analysed in a model adding a measure designed to compensate for the relation between atrial natriuretic peptide and pulmonary capillary wedge pressure. Rapid and graded changes in atrial natriuretic peptide concentration have been reported to occur during interventions that rapidly alter atrial pressures.7 We observed, however, a gradual increase in the calculated ratio of atrial natriuretic peptide concentration to pulmonary capillary wedge pressure in the groups receiving 2 5 mg and 5 mg of ramipril. This observation seems to be due to a gradual return towards the individual baseline plasma concentration in spite of a sustained and significant reduction in pulmonary capillary wedge pressure at 24 hours. This phenomenon may reflect rather slowly acting adaptive mechanisms favouring conservation of the individual plasma concentration of atrial natriuretic peptide.
LIMITATIONS OF THE STUDY
When atrial pressures depend on plasma concentrations of a vasoactive hormone, as they do on atrial natriuretic peptide, and where the study group is not large, significant interactions between atrial natriuretic peptide and the test drug, or involved hormones, might escape detection. The compensatory mechanisms during heart failure are complex, and other vasoactive hormones that were not measured in this study might have had an impact on our results. Although repeated measures of neurohormonal factors would add important information, the amount of blood sampling in this study was restricted to 200 ml to avoid a systematic flaw due to decreased blood volume. Haemodynamic alterations are well recognised during catheterisation studies, and a vasodilative effect of eating on haemodynamics have also been described. '7 In our study the patients ate one hour before the observations obtained at three and 24 hours.
Measurements on these occasions therefore probably include effects of both eating and treatment. The significant fluctuations of hormones and haemodynamics in the placebo group highlights the necessity to include a placebo control in studies on the effects of vasodilatory drugs. Even so, the influences of the experimental procedure itself and of eating, in addition to the effects of the angiotensin converting enzyme inhibitor, may have reduced the possibilities of detecting direct effects of the angiotensin converting enzyme inhibition in our study.
CONCLUSION
In conclusion, whatever the exact mechanism of the relatively higher plasma concentration of atrial natriuretic peptide with a given pulmonary capillary wedge pressure after 24 hours, such an alteration of the relation between atrial natriuretic peptide and central haemodynamics may contribute to the beneficial effects of treatment with an angiotensin converting enzyme inhibitor in patients with congestive heart failure due to ischaemic heart disease.
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